MedTrace Logo

Phase I Study of Milatuzumab for Graft Versus Host Disease

NCT01663766 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-08-19

No results posted yet for this study

Summary

This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.

Conditions

  • GVHD (Acute or Chronic)
  • Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
  • Myelodysplastic Syndrome
  • Chronic Myelogenous Leukemia (CML)
  • Multiple Myeloma (MM)
  • Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)

Interventions

DRUG

milatuzumab

Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01663766 on ClinicalTrials.gov